Cutaneous lymphoproliferative disorders after COVID-19 vaccination: clinical presentation, histopathology, and outcomes

Individual reports described lymphoproliferative disorders (LPDs) after COVID-19 vaccination; however, the relationship between cases is unexamined. We aim to determine if there are cases of cutaneous LPDs associated with COVID-19 vaccination and their outcomes. We present a review of world literatu...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2024, Vol.65 (1), p.48-54
Main Authors: Gordon, Emily R, Kwinta, Bradley D, Schreidah, Celine M, Fahmy, Lauren M, Adeuyan, Oluwaseyi, Queen, Dawn, Trager, Megan H, Magro, Cynthia M, Geskin, Larisa J
Format: Article
Language:English
Subjects:
COVID-19 - prevention & control
COVID-19 Vaccines - adverse effects
Humans
Ki-1 Antigen
Lymphomatoid Papulosis - pathology
Lymphoproliferative Disorders - pathology
Male
Skin Diseases
Skin Neoplasms - pathology
Vaccination - adverse effects
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Individual reports described lymphoproliferative disorders (LPDs) after COVID-19 vaccination; however, the relationship between cases is unexamined. We aim to determine if there are cases of cutaneous LPDs associated with COVID-19 vaccination and their outcomes. We present a review of world literature, vaccine registries, and two unreported cases of LPDs after COVID-19 vaccination. Review of the medical literature, VAERS, and our two cases reveal predominance of Pfizer-BioNTech vaccine, younger patients, and males. All cases resulted in favorable outcomes. Approximately 84% of cases demonstrated CD30+ positivity in their skin biopsies, suggesting that an antigenic trigger may lead to a type IV adaptive immune response, with clonal expansion of CD30+ T-cells and subsequent oncogenic mutational hits eventuating in transient LPDs. LPDs after COVID-19 vaccination appear in the context of the same vaccines (proportionally to their global market shares), share clinical and pathological findings, and have indolent, self-limited character.
ISSN:1042-8194
1029-2403
DOI:10.1080/10428194.2023.2270766